Takeda Pharmaceutical Company Limited (FRA:TKDA)

Revenue Breakdown 2

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
GI Revenue (Post-FY2024 Reporting)	1.40T	1.36T
Rare Diseases Revenue (Post-FY2024 Reporting)	748.20B	752.82B
PDT Revenue (Post-FY2024 Reporting)	1.04T	1.03T
Oncology Revenue (Post-FY2024 Reporting)	568.70B	560.43B
Vaccines Revenue	60.50B	55.41B
Neuroscience Revenue (Post-FY2024 Reporting)	423.80B	565.82B
Other Product Revenue (Post-FY2024 Reporting)	228.00B	257.39B
Revenue (Total)	4.52T	4.58T

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013
Japan Revenue	433.20B	418.46B
United States Revenue	2.21T	2.38T
Europe and Canada Revenue	1.09T	1.06T
Latin America Revenue	236.00B	235.85B
China Revenue	198.90B	191.74B
Asia (ex-Japan & China) Revenue	96.90B	99.39B
Asia (ex-Japan) Revenue	295.80B	291.13B
Russia / CIS Revenue	70.90B	72.36B
Other Geographic Revenue	123.90B	128.85B
Revenue (Other)	53.50B	1.00M
Revenue (Total)	4.52T	4.58T

Updated Dec 31, 2025. Data Source: Fiscal.ai.